Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
Int Braz J Urol. 2019 Jan-Feb;45(1):10-22. doi: 10.1590/S1677-5538.IBJU.2018.0510.
To systematically assess the effectiveness and safety of retrograde flexible ureteroscopy (FURS) versus percutaneous nephrolithotomy (PCNL) in treating intermediate-size renal stones (2-3cm).
PubMed, Ovid MEDLINE, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE were researched to identify relevant studies up to May 2018. Article selection was performed through the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. The Newcastle-Ottawa Scale was applied to assess the methodological quality of case-control studies.
Six retrospective case-controlled trials were included for meta-analysis. The pooled results showed that PCNL was associated with a higher initial stone-free rate (SFR). After more complementary treatments, FURS provided a final SFR (OR: 1.69; 95% CI, 0.93-3.05; P = 0.08) comparable to that achieved by PCNL. PCNL was associated with a higher rate of overall intraoperative complications (OR: 1.48; 95% CI, 1.01-2.17; P = 0.04) and longer hospital stay (MD: 2.21 days; 95% CI, 1.11 to 3.30; P < 0.001). Subgroup analysis by Clavien-graded complication showed PCNL had significantly higher rates of minor complications (OR: 1.58; 95% CI, 1.04-2.41; P = 0.03). No significant difference was noted in major complications (OR: 1.14; 95% CI, 0.53-2.45; P = 0.73) or operative times (MD: -9.71 min; 95% CI, -22.02 to 2.60; P = 0.12).
Multisession FURS is an effective and safe alternative to PCNL for the management of intermediate-size renal stones (2-3cm). It is advisable to balance the benefits and risks according to the individual characteristics of patients and to decide with patients by discussing the advantages and disadvantages of each procedure.
系统评估逆行软性输尿管镜(FURS)与经皮肾镜碎石术(PCNL)治疗 2-3cm 中等大小肾结石的有效性和安全性。
检索了 PubMed、Ovid MEDLINE、Web of Science、Cochrane 对照试验中心注册库(CENTRAL)和 EMBASE,以确定截至 2018 年 5 月的相关研究。根据系统评价和荟萃分析的首选报告项目制定了搜索策略来进行文章选择。采用纽卡斯尔-渥太华量表来评估病例对照研究的方法学质量。
纳入 6 项回顾性病例对照研究进行荟萃分析。汇总结果显示,PCNL 初始结石清除率(SFR)更高。经过更多的补充治疗后,FURS 的最终 SFR(OR:1.69;95%CI,0.93-3.05;P=0.08)与 PCNL 相当。PCNL 术中总体并发症发生率更高(OR:1.48;95%CI,1.01-2.17;P=0.04),住院时间更长(MD:2.21 天;95%CI,1.11-3.30;P<0.001)。根据 Clavien 分级并发症进行的亚组分析显示,PCNL 有更高的轻微并发症发生率(OR:1.58;95%CI,1.04-2.41;P=0.03)。但主要并发症发生率无显著差异(OR:1.14;95%CI,0.53-2.45;P=0.73)或手术时间(MD:-9.71 分钟;95%CI,-22.02 至 2.60;P=0.12)。
多疗程 FURS 是治疗 2-3cm 中等大小肾结石的有效且安全的替代方法。应根据患者的个体特征权衡利弊,并与患者讨论每种手术的优缺点,共同决定治疗方案。